<DOC>
	<DOCNO>NCT01448772</DOCNO>
	<brief_summary>This comparative study assess bioavailability propose alternate dosage form current FDA-approved brand product .</brief_summary>
	<brief_title>Comparative Bioavailability Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>1 . Male female healthy subject 18 55 year age , inclusive . 2 . Subjects must body mass index ( BMI ) within 19 29.9 kg/m2 , inclusive weigh minimum 50 kg ( 110 pound ) . 3 . Subjects must general good health determine medical history , physical examination , laboratory evaluation conduct screen visit upon admission clinic . Examination include thorough examination oral cavity abnormal finding . 4 . Subjects must nonsmoker , define use tobacco product past six month . Negative result urine cotinine test conduct Screening . 5 . Subjects must able provide inform consent risk benefit explain , willing comply study procedure . 6 . Female subject childbearing potential must pregnant nursing ; must surgically sterile ; one year postmenopausal ; hormonal contraceptive agent ( ) , diaphragm condom spermicidal foam jelly , IUD least three month prior drug administration agree use method contraception least one month last drug administration . 7 . Negative urine pregnancy test screen prior drug administration period . 8 . Negative HIV 1 , hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen within 30 day prior start study . 9 . Negative result screen drug abuse Screening Day1 ( checkin ) prior drug administration study period . 1 . Known hypersensitivity allergy dronabinol , Marinol , marijuana , hashish , sesame oil . 2 . Have participate investigational trial within 30 day six halflives test drug 's biologic activity , whichever longer , time first study dose study . 3 . Presence visible sign infection , mucositis , cold sore , lesion , local irritation , periodontal disease oral cavity abnormal find oral cavity . In addition , evidence piercings tongue , lip , anywhere oral cavity history oral cavity piercings . 4 . Have donate receive blood blood product within 30 day prior first study dose . 5 . Have receive prescription drug ( exclude hormonal contraceptive ) within 14 day study drug administration , overthecounter drug within seven day study drug administration , and/or vitamin herbal supplement within three day study drug administration . 6 . Significant bradycardia tachycardia define rest heart rate &lt; 45 bpm &gt; 100 bpm , respectively . 7 . Clinical evidence either hypotension ( define systolic blood pressure &lt; 90 mmHg diastolic blood pressure &lt; 50 mmHg ) , hypertension ( define systolic blood pressure &gt; 139 mmHg diastolic blood pressure &gt; 89 mmHg ) . 8 . Any history clinically significant organ system ( cardiovascular , neurological , hepatic , hematopoietic , renal , pulmonary , endocrine , gastrointestinal ) disorder ongoing infectious disease ; condition might interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk . 9 . Use marijuana ( directly indirectly ) within 90 day prior drug administration course study . 10 . History treatment alcohol abuse , significant mental illness , physical dependence opioid , barbiturate , amphetamine , cocaine , benzodiazepine past 10 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Dronabinol</keyword>
	<keyword>fast</keyword>
</DOC>